(Q47738795)

English

Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy

scientific article published on 16 April 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464527

Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464527

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

0 references

3

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464527

object named as

M Dudareva

1

0 references

5

object named as

K Marsh

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464527

author name string

L Andrews

2

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464527

P Bejon

4

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464527

J Mwacharo

6

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464527

O Kai

7

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464527

A Nicosia

8

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464527

A V S Hill

9

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464527

language of work or name

0 references

publication date

16 April 2009

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464527

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464527

27

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464527

27

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464527

3501-3504

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464527

The global distribution of clinical episodes of Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.080

7 January 2021

The burden of malaria mortality among African children in the year 2000.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.080

7 January 2021

Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.080

7 January 2021

Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.080

7 January 2021

A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.080

7 January 2021

Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.080

7 January 2021

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.080

7 January 2021

A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.080

7 January 2021

Multiple immunizations with adenovirus and MVA vectors improve CD8+ T cell functionality and mucosal homing

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.080

7 January 2021

Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.080

7 January 2021

Chimpanzee adenovirus vaccine protects against Zaire Ebola virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.080

7 January 2021

Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.080

7 January 2021

Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.080

7 January 2021

A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.080

7 January 2021

Replication-defective vector based on a chimpanzee adenovirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.080

7 January 2021

Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.080

7 January 2021

Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.080

7 January 2021

Generation of an adenoviral vaccine vector based on simian adenovirus 21.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.080

7 January 2021

Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.080

7 January 2021

Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.080

7 January 2021

Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.080

7 January 2021

Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.080

7 January 2021

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.080

7 January 2021

Immune responses to adenovirus and adeno-associated virus in humans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.080

7 January 2021

Identifiers

10.1016/J.VACCINE.2009.03.080

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464527

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464527

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47738795&oldid=2169184382"